The fourth-generation SMI4027 MUX/CMU and SMI4037 CDR/DEMUX optical communications chipset support data rates from 39.8 to 44.6 Gbits/s and incorporates a user-enabled differential phase-shift keying ...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...
Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results